| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 0.10 | 16.7% | 52.4% |
| Total Income | 0.10 | 16.7% | 52.4% |
| Expenditure | 14.33 | 10.3% | 7.6% |
| PBT | — | ||
| Net Profit | -30.91 | 61.1% | 126.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -2.18 | 11.0% | 581.3% |
BioXcel Therapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 7:25 am
Summary
BioXcel Therapeutics reported its Q3 2025 financial results, with net revenue from IGALMI® at $98 thousand, down from $214 thousand in Q3 2024. Research and Development expenses increased to $8.7 million, while SG&A expenses decreased to $5.4 million. The company reported a net loss of $30.9 million for the quarter. They are preparing for an sNDA submission for IGALMI® and advancing pre-launch and commercial readiness initiatives.
Key Highlights
- 1
BioXcel Therapeutics reported net revenue from IGALMI® of $98 thousand for the third quarter of 2025, compared to $214 thousand for the same period in 2024.
- 2
Research and Development expenses were $8.7 million for the third quarter of 2025, compared to $5.1 million for the same period in 2024.
- 3
Selling, General and Administrative expenses were $5.4 million for the third quarter of 2025, compared to $7.7 million for the same period in 2024.
- 4
The company reported a net loss of $30.9 million for the third quarter of 2025, compared to a net loss of $13.7 million for the same period in 2024.
- 5
Cash and cash equivalents and restricted cash totaled $37.3 million as of September 30, 2025.
- 6
The company plans to submit early in the first quarter of 2026 a supplemental New Drug Application (sNDA) seeking FDA approval for the at-home use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia.
Management Comments
Vimal Mehta
Ph.D.
“We are focused on the next phase of our journey, preparing for an sNDA submission and advancing pre-launch and commercial readiness initiatives,” “BXCL501 has the potential to redefine the treatment of agitation, addressing an at-home market opportunity of 57 to 77 million annual episodes in the U.S. alone. This momentum lays the foundation for meaningful, long-term growth and value creation as we work to make BXCL501 accessible to patients at home, where they need it most.”
Informational and educational content only. Not investment advice.